Merrill Lynch Upgrades Affymax (AFFY) to Neutral
More News related to Upgrades
- D.A. Davidson Upgrades Columbia Sportswear (COLM) to Buy
- Raymond James Upgrades Assoc Banc-Corp (ASBC) to Strong Buy
- Diana Shipping (DSX) Continuing Higher On the Back of a Two-Notch Upgrade
- BB&T Capital Upgrades Standard Motor Products (SMP) to Buy
- Bank of America Upgrades Semi Manufacturing International (SMI) to Neutral
Merrill Lynch upgrades Affymax (AFFY) from Underperform to Neutral.
Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions.
Stocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
